Company Description
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development.
The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices.
In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property.
The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024.
Quantum BioPharma Ltd., is headquartered in Toronto, Canada.
| Country | Canada |
| Founded | 1998 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Zeeshan Saeed |
Contact Details
Address: 55 University Ave., Suite 1003 Toronto, ON M5J 2H7 Canada | |
| Website | fsdpharma.com |
Stock Details
| Ticker Symbol | QNTM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001771885 |
| CUSIP Number | 35954B206 |
| ISIN Number | CA74764Y2050 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lakshmi P. Kotra BPHARM, Ph.D. | Chief Executive Officer of Lucid and Director |
| Zeeshan Saeed | Founder, Chief Executive Officer, President and Executive Co-Chairman |
| Anthony John Durkacz | Founder and Executive Co-Chairman |
| Nathan Coyle CPA | Chief Financial Officer |
| Donal Carroll CPA | Chief Operating Officer |
| Maryann Adesso | Corporate Secretary |
| Randell Mack | President of FSD BioSciences |
| Dr. Andrzej Chruscinski M.D., Ph.D. | Vice President of Clinical and Scientific Affairs of Lucid |
| Kevin Cassidy | Vice President of Quality-Lucid |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 16, 2024 | 6-K | Report of foreign issuer |
| Sep 9, 2024 | 6-K | Report of foreign issuer |
| Sep 9, 2024 | 6-K | Report of foreign issuer |
| Aug 30, 2024 | 6-K | Report of foreign issuer |
| Aug 27, 2024 | 424B5 | Filing |
| Aug 27, 2024 | 6-K | Report of foreign issuer |
| Aug 26, 2024 | 6-K | Report of foreign issuer |
| Aug 19, 2024 | 6-K/A | Filing |
| Aug 16, 2024 | 6-K | Report of foreign issuer |
| Aug 15, 2024 | 6-K | Report of foreign issuer |